6300-95-4

Upstream product

• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 57-13-6 urea 
• 621-82-9 Cinnamic acid 
• 140-10-3 (E)-3-phenylacrylic acid 
• 112380-45-7 2-methylsulfanyl-6-phenyl-5,6-dihydro-3H-pyrimidin-4-one 
• 103-26-4 methyl cinnamate 
• 3646-50-2 3-Amino-3-phenylpropionic acid 
• 100-52-7 benzaldehyde 
• 471259-71-9 (RS)-3-amino-3-phenyl-propionic acid hydrochloride 
• 2033-24-1 cycl-isopropylidene malonate 
• 591-51-5 phenyllithium 
• 6335-76-8 3-amino-3-phenylpropionic acid ethyl ester 
• 5962-06-1 trans-cinnamoylurea 
• 21428-07-9 β-phenyl-propionic acid β-ureide 

Downstream Products

• 13345-09-0 6-phenyluracil 
• 101012-73-1 4-(2,6-dioxo-hexahydro-pyrimidin-4-yl)-benzenesulfonyl chloride 
• 21428-07-9 β-phenyl-propionic acid β-ureide 
• 7614-93-9 1,3-diphenyl-1-butene 
• 621-82-9 Cinnamic acid 
• 3646-50-2 3-Amino-3-phenylpropionic acid 
• 84796-63-4 β-phenylalanine 
• 90946-83-1 5,6-dihydro-6-(4-nitrophenyl)pyrimidine-2,4(1H,3H)-dione 
• 107626-81-3 4-(2,6-dioxo-hexahydro-pyrimidin-4-yl)-benzenesulfonic acid 
• 99056-54-9 4-(2,6-dioxo-hexahydro-pyrimidin-4-yl)-benzenesulfonic acid amide 

Relevant academic research and scientific papers

A different role of Meldrum's acid in the Biginelli reaction

A Biginelli-type condensation using Meldrum's acid has been accomplished in refluxing AcOH to give 6-substituted dihydropyrimidine-2,4-(1H,3H)-diones. In contrast to other aldehydes, the three-component reaction with salicylaldehyde led to an oxygen-bridged pyridine. A reaction mechanism is proposed.

DIHYDROURACIL COMPOUNDS AS ANTI-ICTOGENIC OR ANTI-EPILEPTOGENIC AGENTS

Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent or treat ictogenesis, epileptogenesis, or epileptogenesis-associated conditions. Methods for preparing the compounds of the invention are also described. Particularly preferred compounds of the invention include Formula 1 as described herein.

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Synthesis and evaluation of anticonvulsant activities of some new arylhexahydropyrimidine-2,4-diones

In this study, some new 3-alkyl-6-arylhexahydropyrimidine-2,4-dione derivatives were synthesized as anticonvulsant agents. 6-Arylhexahydropyrimidine-2,4-diones which were used as starting materials in the synthesis of the compounds were prepared in acidic

Thermal reaction of cinnamic acid and of β-styrylphosphonic acid with urea

The thermal reaction of b-styrylphosphonic acid under experimental conditions similar to those applied to cinnamic acid and to methyl cinnamate to provide 6-phenyl-5,6-dihydrouracil, led to the formation of the novel 6-phenyl-5,6-dihydro-4-phosphorylamide-(1H,3H)-2-pyrimidinone.

A New Route to 5,6-Dihydropyrimidin-4(3H)-ones

The addition reaction of 2,4-bis(methylthio)pyrimidine or 2,4-dimethoxypyrimidine with organolithium reagents produces unstable 6-substituted 2,4-bis(methylthio)-5,6-dihydropyrimidines and 2,4-dimethoxy-5,6-dihydropyrimidines, respectively.The regioselect